High-glucose-induced structural changes in the heparan sulfate proteoglycan, perlecan, of cultured human aortic endothelial cells

Biochimica et Biophysica Acta - General Subjects

Volumn 1672, Issue 1, 2004, Pages 36-45

  Vogl Willis, Catherine A ^a   Edwards, Iris J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; BAEC; Chondroitin sulfate; CS; Dermatan sulfate; Diabetes; DS; Endothelial cell; GAG; GBM; Glomerular basement membrane; Glycosaminoglycan; HAEC; Heparan sulfate; HS; Human aortic endothelial cell; Hyperglycemia; Perlecan; PG; Proteoglycan

Indexed keywords

CORE PROTEIN; GLUCOSAMINE; GLUCOSE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; PERLECAN; PROTEOHEPARAN SULFATE; SERINE; SODIUM SULFATE; TRITIUM;

AORTA; ARTICLE; CELL CULTURE; CHEMICAL STRUCTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYPEROSMOLALITY; IMMUNOPRECIPITATION; IN VITRO STUDY; PRIORITY JOURNAL; SULFATION;

ANIMALS; AORTA; CATTLE; DIABETES MELLITUS; ENDOTHELIAL CELLS; GLUCOSE; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; MYOCYTES, SMOOTH MUSCLE; SULFATES;

EID: 1642619054     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2004.02.005     Document Type: Article

References (43)

1. Colwell J.A. Vascular thrombosis in type II diabetes mellitus. Diabetes. 42:1993;8-11.
2. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 16:1993;434-444.
3. Wilson W.F., Cupples L.A., Kannel W.B. Is hyperglycemia associated with cardiovascular disease? The Framingham Study. Am. Heart J. 121(2):1991;586-590.
4. Castellot J.J. Jr., Addonizio M.L., Rosenberg R., Karnovsky M.J. Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth. J. Cell Biol. 90:1981;372-379.
5. Nugent M.A., Karnovsky M.J., Edelman E.R. Vascular cell-derived heparan sulfate shows coupled inhibition of basic fibroblast growth factor binding and mitogenesis in vascular smooth muscle cells. Circ. Res. 73:1993;1051-1060.
6. Sivaram P., Obunike J.C., Goldberg I.J. Lysolecithin-induced alteration of subendothelial heparan sulfate proteoglycans increases monocyte binding to matrix. J. Biol. Chem. 270(50):1995;29760-29765.
7. Wasty F., Alavi M.Z., Moore S. Distribution of glycosaminoglycans in the intima of human aortas: changes in atherosclerosis and diabetes mellitus. Diabetologia. 36:1993;316-322.
8. Parthasarathy N., Spiro R.G. Effect of diabetes on the glycosaminoglycan component of the human glomerular basement membrane. Diabetes. 31(8 Pt 1):1982;738-741.
9. Vernier R.L., Steffes M.W., Sisson-Ross S., Mauer S.M. Heparan sulfate proteoglycan in the glomerular basement membrane in type 1 diabetes mellitus. Kidney Int. 41:1992;1070-1080.
10. Kanwar Y.S., Linker A., Farquhar M.G. Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion. J. Cell Biol. 86(2):1980;688-693.
11. Tamsma J.T., van den Born J., Bruijn J.A., Assmann K.J.M., Weening J.J., Berden J.H.M., Wieslander J., Schrama E., Hermans J., Veerkamp J.H., Lemkes H.H.P.J., van der Woude F.J. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulfate in the glomerular basement membrane. Diabetologia. 37:1994;313-320.
12. Van Det N.F., Van den Born J., Tamsma J.T., Verhagen N., Berden J.H.M., Bruijn J., Daha M., Van der Woude F.J. Effects of high glucose on the production of heparan sulfate proteoglycan by mesangial and epithelial cells. Kidney Int. 49:1996;1079-1089.
13. Evanko S.P., Raines E., Ross R., Gold L.I., Wight T.N. Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-β Am. J. Pathol. 152:1998;533-546.
14. Saku T., Furthmayr H. Characterization of the major heparan sulfate proteoglycan secreted by bovine aortic endothelial cells in culture. J. Biol. Chem. 264:1989;3514-3523.
15. Pillarisetti S., Klein M.G., Goldberg I.J. Identification of a heparin-releasable lipoprotein lipase binding protein from endothelial cells. J. Biol. Chem. 267:1992;16517-16522.
16. Chang M.Y., Potter-Perigo S., Tsoi C., Chait A., Wight T.N. Oxidized low density lipoproteins regulate synthesis of monkey aortic smooth muscle cell proteoglycans that have enhanced native low density lipoprotein binding properties. J. Biol. Chem. 275(7):2000;4766-4773.
17. Edwards I.J., Wagner W.D. Cell surface heparan sulfate proteoglycan and chondroitin sulfate proteoglycan of arterial smooth muscle cells. Am. J. Pathol. 140(1):1992;193-205.
18. Edwards I.J., Wagner W.D. Distinct synthetic and structural characteristics of proteoglycans produced by cultured artery smooth muscle cells of atherosclerosis- susceptible pigeons. J. Biol. Chem. 263(20):1988;9612-9620.
19. Yanagashita M., Salustri A., Hascall V. Specific activity of radiolabeled hexosamines in metabolic labeling experiments. Methods Enzymol. 179:1989;435-446.
20. Wasteson A. A method for the determination of the molecular weight and molecular-weight distribution of chondroitin sulfate. J. Chromatogr. 59:1971;87-97.
21. Hiscock D.R.R., Canfield A., Gallagher J.T. Molecular structure of heparan sulfate synthesized by bovine aortic endothelial cells. Biochim. Biophys. Acta. 1244:1995;104-112.
22. Kaji T., Yamada A., Miyajima S., Yamamoto C., Fujiwara Y., Wight T.N., Kinsella M.G. Cell density-dependent regulation of Proteoglycan synthesis by transforming growth factor-β1 in cultured bovine aortic endothelial cells. J. Biol. Chem. 275(2):2000;1463-1470.
23. Ebara T., Conde K., Kako Y., Liu Y., Xu Y., Ramakrishnan R., Goldberg I.J., Shachter N.S. Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. J. Clin. Invest. 105:2000;1807-1818.
24. Hadad S.J., Michelacci Y.M., Schor N. Proteoglycans and glycosaminoglycans synthesized in vitro by mesangial cells from normal and diabetic rats. Biochim. Biophys. Acta. 1290:1996;18-28.
25. Danielson K.G., Martinez-Hernandez A., Hassel J.R., Iozzo R.V. Establishment of a cell line from the EHS tumor: biosynthesis of basement membrane constituents and characterization of a hybrid proteoglycan containing heparan and chondroitin sulfate chains. Matrix. 12:1992;22-35.
26. Kokenyesi R., Silbert J.E. Formation of heparan sulfate or chondroitin/dermatan sulfate on recombinant domain 1 of mouse perlecan expressed in Chinese hamster ovary cells. Biochem. Biophys. Res. Commun. 211(1):1995;262-267.
27. Tapanadechopone P., Hassell J.R., Rigatti B.R., Couchman J.R. Localization of glycosaminoglycan substitution sites on domain V of mouse perlecan. Biochem. Biophys. Res. Commun. 265(3):1999;680-690.
28. Rasmussen R., Rapraeger A. Altered structure of the hybrid cell surface proteoglycan of mammary epithelial cells in response to transforming growth factor-β J. Cell Biol. 107:1988;1959-1967.
29. Roden L. Lennarz W.J. The Biochemistry of Glycoproteins and Proteoglycans. 1980;267-271 Plenum, New York.
30. Bourden M.A., Krusius T., Campbell S., Schwartz N.B., Ruoslahti E. Identification and synthesis of a recognition signal for the attachment of glycosaminoglycans to proteins. Proc. Natl. Acad. Sci. 84(10):1987;3194-3198.
31. Esko J.D., Zhang L. Influence of core protein sequence on glycosaminoglycan assembly. Curr. Opin. Struct. Biol. 6(5):1996;663-670.
32. Dolan M., Horchar T., Rigatti B., Hassell J.R. Identification of sites in domain I of perlecan that regulate heparan sulfate synthesis. J. Biol. Chem. 272(7):1997;4316-4322.
33. Kaiser N., Sasson S., Feener E.P., Boukobza-Vardi N., Higashi S., Moller D.E., Davidheiser S., Przybylski R.J., King G.L. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes. 42(1):1993;80-89.
34. Wertheimer E., Sasson S., Cerasi E., Ben-Neriah Y. The ubiquitous glucose transporter GLUT-1 belongs to the glucose-regulated protein family of stress- inducible proteins. Proc. Natl. Acad. Sci. 88(6):1991;2525-2529.
35. Mandarino L.J., Finlayson J., Hassell J.R. High glucose downregulates glucose transport activity in retinal capillary pericytes but not endothelial cells. Invest. Ophthalmol. Visual Sci. 35(3):1994;964-972.
36. Aronson D., Rayfield E.J. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc. Diabetol. 2002;1:1. (Review).
37. Nishikawa T., Edelstein D., Du X.L., Yamagishi S., Matsumura T., Kaneda Y., Yorek M.A., Beebe D., Oates P.J., Hammes H.-P., Giardino I., Brownlee M. Nature. 404:2000;787-790.
38. Yayon A., Klagsbrun M., Esko J.D., Leder P., Ornitz D.M. Cell surface, heparin-like molecules are required for binding basic fibroblast growth factor to its high affinity receptor. Cell. 64:1991;841-848.
39. Nugent M.A., Edelman E.R. Kinetics of basic fibroblast growth factor binding to its receptor and heparin sulfate proteoglycan: a mechanism for cooperativity. Biochemistry. 31:1992;8876-8883.
40. Forsten K.E., Courant N.A., Nugent M.A. Endothelial proteoglycans inhibit bFGF binding and mitogenesis. J. Cell. Physiol. 172:1997;209-220.
41. Nugent M.A., Iozzo R.V. Fibroblast growth factor-2. Int. J. Biochem. Cell Biol. 32:2000;115-120.
42. Nugent M.A., Nugent H.M., Iozzo R.V., Sanchack K., Edelman E.R. Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia. Proc. Natl. Acad. Sci. U. S. A. 97:2000;6722-6727.
43. Vogl-Willis C.A., Edwards I.J. High glucose-induced alterations in subendothelial matrix perlecan leads to increased monocyte binding. Arterioscler. Thromb. Vasc. Biol. 2004;. in press.